Loading clinical trials...

Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

NCT00388440•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy children (12-18 months of age) and blood samples were collected at two time points (before vaccination and after vaccination).

Eligibility

Age

1 - 1 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•A male or female infant between 12 and 18 months of age at the time of the vaccination
•Written informed consent obtained from the parents or guardians of the subject.
•Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria

•Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the dose of study vaccine
•Previous vaccination against mumps and/or rubella
•History of, or intercurrent, measles, mumps, and/or rubella disease
•Known exposure to measles, mumps or rubella within 30 days prior to the start of the study
•Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

Key Dates

Start Date

November 1, 2000

Primary Completion Date

April 1, 2001

Completion Date

April 1, 2001

Last Updated

September 20, 2016

Enrollment

150

ACTUAL participants

Conditions

RubellaMumpsMeasles

Interventions

MMR vaccine (Priorix)

BIOLOGICAL

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

NCT07112846

ExanthemaDengue Fever+3 more

View study

COMPLETEDPHASE4

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

NCT03460002

Measles VaccinationOral Polio Vaccine+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 20, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

Inclusion Criteria

Exclusion Criteria

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

Co-administration Study of OCV, TCV and MR

Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants